



### **Kala Pharmaceuticals to Present at the Targeting Ocular Disorders Conference**

Waltham, Mass., September 23, 2013 – Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to treat ocular diseases, announced today that Guillaume Pfefer, Ph.D., Kala's President and Chief Executive Officer, is scheduled to present at the Targeting Ocular Disorders Conference being held September 26-27, 2013 in Boston, MA. The presentation, entitled "Breakthrough Solutions for Ocular Disease" will take place on Thursday, September 26, 2013 at 3:30 p.m. ET during the Science for Success session. During his presentation, Dr. Pfefer will discuss the significant unmet need for improved therapeutic approaches to address the rapidly growing ocular disease market. He will highlight Kala's Mucus Penetrating Particles (MPPs) which are designed to treat both front and back of the eye disease with improved therapeutic profiles.

#### **About Kala Pharmaceuticals**

Kala Pharmaceuticals, Inc. is advancing innovative treatments for ocular diseases addressing significant unmet needs in both front and back of the eye based on the Company's proprietary Mucus Penetrating Particle (MPP) technology. Kala's topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film. Kala's product development pipeline includes: a 1% formulation of loteprednol etabonate (1% LE-MPP) to treat post-surgical ocular inflammation and pain, expected to enter a pivotal clinical study in 2014; a 0.25% LE-MPP formulation for dry eye, blepharitis, and retinal disease, expected to enter clinical trials in 2014, and a topically applied receptor tyrosine kinase inhibitor (RTKi-MPP) for the treatment of wet age-related macular degeneration (AMD), which is advancing toward selection of a clinical candidate in 2014.

Kala's approach to penetrating mucus layers also has potential application in other disease areas, such as respiratory, female reproductive tract, and gastrointestinal diseases, and in these areas the Company will seek partners to out-license its breakthrough technology. Kala was founded by leaders in the fields of nanomedicine and biopharmaceutical engineering, maintains an esteemed group of advisors including co-founder and MIT professor Dr. Robert Langer, and is backed by leading investors including Lux Capital, Polaris Venture Partners, Third Rock Ventures, and Crown Venture Fund, LLC. For more information, please visit [www.kalarx.com](http://www.kalarx.com).

#### **Contact:**

*Kala Pharmaceuticals, Inc.*

*Tel: 781 810 4748*

*info@kalarx.com*

#### **Media:**

*Gina Nugent*

*The Yates Network*

*gina@theyatesnetwork.com*